| pegylated liposomal doxorubicin / Generic mfg. |
NCT00561743: A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients |
|
|
| Completed | 2 | 50 | US | Bortezomib + pegylated liposomal doxorubicin HCl + dexamethasone | Janssen-Ortho Inc., Canada | Multiple Myeloma | 05/07 | 05/07 | | |
NCT00222105: A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life |
|
|
| Completed | 2 | 25 | NA | Doxil, pegylated liposomal doxorubicin, Thalidomide, thalidomid, Dexamethasone, decadron | University of Kansas Medical Center, Ortho Biotech, Inc. | Multiple Myeloma | 04/09 | 07/09 | | |
NCT00706953: A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib |
|
|
| Withdrawn | 2 | 0 | US | bortezomib; pegylated liposomal doxorubicin | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Centocor Ortho Biotech Services, L.L.C. | Multiple Myeloma | 06/10 | 06/10 | | |
NCT00148317: Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma |
|
|
| Completed | 2 | 38 | US | Bortezomib, velcade, dexamethasone, decadron, liposomal doxorubicin, cyclophoshamide, cytoxan, filgrastim, neupogen | Weill Medical College of Cornell University, Millennium Pharmaceuticals, Inc. | Multiple Myeloma | 02/11 | 11/12 | | |
NCT00366106: Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma |
|
|
| Terminated | 2 | 32 | US | bortezomib, Velcade, dexamethasone, Decadron, doxorubicin HCl liposome, Doxil | Accelerated Community Oncology Research Network, Millennium Pharmaceuticals, Inc. | Multiple Myeloma | 03/11 | 03/11 | | |
NCT00851552: Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment |
|
|
| Terminated | 2 | 9 | US | rituximab, bortezomib, pegylated liposomal doxorubicin hydrochloride, gene expression analysis, polymerase chain reaction, polymorphism analysis, proteomic profiling, flow cytometry, laboratory biomarker analysis | Roswell Park Cancer Institute, Ortho Biotech, Inc. | Lymphoma | 09/11 | 09/11 | | |
NCT00184002: Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas |
|
|
| Completed | 2 | 68 | US | Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone | University of Southern California, Ortho Biotech, Inc. | Non-Hodgkin's Lymphoma | 12/12 | 05/13 | | |
NCT00617591: Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM) |
|
|
| Completed | 2 | 57 | US | Lenalidomide, Revlimid®, Pegylated Liposomal Doxorubicin (PLD), Doxil®, Dexamethasone, Decadron® | H. Lee Moffitt Cancer Center and Research Institute, Celgene Corporation, Ortho Biotech Clinical Affairs, L.L.C. | Multiple Myeloma | 04/13 | 04/13 | | |
NCT01492881: Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma |
|
|
| Withdrawn | 2 | 0 | US | Vorinostat, Zolina, Bortezomib, Velcade, pegylated liposomal doxorubicin, Doxil | UNC Lineberger Comprehensive Cancer Center, Merck Sharp & Dohme LLC | Multiple Myeloma | 01/15 | 01/17 | | |
NCT00255801: Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma |
|
|
| Completed | 2 | 37 | US | Targretin® (bexarotene), pegylated liposomal doxorubicin hydrochloride | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI), Tibotec Pharmaceutical Limited, M.D. Anderson Cancer Center, NYU Langone Health, Hackensack Meridian Health, Roswell Park Cancer Institute | Lymphoma | 10/17 | 10/17 | | |
NCT00244985: Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma |
|
|
| Completed | 1/2 | 42 | US | rituximab, pegylated liposomal doxorubicin hydrochloride | Roswell Park Cancer Institute, Ortho Biotech, Inc. | Lymphoma | 08/08 | 12/12 | | |
